Salbutamol Use in Pregnancy

FDA Classification and Regulatory Context

• The FDA classifies oral salbutamol as Pregnancy Category C, indicating animal reproduction studies have revealed adverse effects on the fetus, and studies in women and animals are not available, so drugs should be given only if potential benefit justifies potential risk, as stated by the European Heart Journal 1
• The FDA replaced the ABCDX pregnancy category system in 2015 with descriptive labeling under the Pregnancy and Lactation Labeling Rule, but Category C remains the historical classification for oral salbutamol, according to the European Heart Journal and Ophthalmology 1, 2

Important Distinction: Route of Administration Matters

• Inhaled salbutamol has a more favorable safety profile and is classified as Category A by the Australian Therapeutic Goods Administration, indicating it has been taken by a large number of pregnant women without increase in fetal malformations 3
• The oral formulation carries greater systemic exposure and different risk considerations compared to inhaled forms, as noted by Praxis Medical Insights 3

Clinical Safety Data and Real-World Experience

• Despite the Category C classification, there is reassuring safety data for albuterol use in pregnancy from 6,667 pregnant women, including 1,929 with asthma and 1,599 who took beta2-agonists, according to Praxis Medical Insights 3

Preferred Alternative: Inhaled Route

• Inhaled salbutamol is strongly preferred over oral formulation during pregnancy because it has more extensive safety evidence and lower systemic exposure, as stated by Praxis Medical Insights 3
• Inhaled asthma medications including salbutamol have been used for many years without documentation of adverse effects on the fetus, according to Praxis Medical Insights 3
• The risk of structural anomalies with inhaled salbutamol is similar to that of the general population, as noted by Praxis Medical Insights 3

Risk-Benefit Framework for First Trimester

• Uncontrolled respiratory disease poses greater risk to the fetus than asthma medications, including risks of perinatal mortality, preeclampsia, and low birth weight, according to Praxis Medical Insights 3
• It is preferable to keep asthma controlled during pregnancy rather than suspending medication, as stated by Praxis Medical Insights 3